Sign In
Buy HEPA
$0.0600
-0.0030 (-4.76%)
At Close: Jun 03, 2026
EDISON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment
Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress
09:50am, Thursday, 29'th Apr 2021
EDISON, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) - dr
HEPA Stock Price Increases Over 5% Pre-Market: Why It Happened
08:37am, Tuesday, 23'rd Mar 2021
The stock price of Hepion Pharmaceuticals Inc (NASDAQ: HEPA) increased by over 5% pre-market. This is why it happened.
EDISON, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) - dr
Hepion Pharmaceuticals Announces Pricing of Public Offering
06:45am, Tuesday, 16'th Feb 2021
EDISON, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment
Attractive Risk-Reward Profile For Hepion Pharmaceuticals
11:37am, Friday, 12'th Feb 2021
Hepion's leading candidate CRV431 may have the best anti-fibrotic effect among the numerous NASH candidates. CRV431's analogs have been widely studied in various clinical trials, and were proven to be
Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor Conferences
08:00am, Tuesday, 05'th Jan 2021
EDISON, NJ / ACCESSWIRE / January 5, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeuti
CRV431 Demonstrated to be Generally Safe and Well Tolerated Clinically Significant Reductions in Important Biomarkers, ALT and AST, Observed in 28 Days Study Continuing with Higher Dose EDISON, NJ / A
- DSMB Review After Completion of the First Dose Cohort Affirmed No Safety or Tolerability Concerns with CRV431 in NASH Patients - - DSMB Recommended the AMBITION Study Continue with Final Dosing Coho
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 for COVID-19
07:30am, Tuesday, 22'nd Dec 2020
- IND Expands Potential Indications for CRV431 Beyond NASH to Include COVID-19 - - CRV431 Poised to Move Directly into Phase 2 Clinical Study for COVID-19 - - Company May Seek Partnership(s) for COVID
Terns Pharmaceuticals to Present Clinical Data on Improved TERN-101 Tablet Formulation at the Paris NASH Digital Experience
12:00am, Thursday, 22'nd Oct 2020
Terns Pharmaceuticals to Present Clinical Data on Improved TERN-101 Tablet Formulation at the Paris NASH Digital Experience
Regulatory News: POXEL (Euronext – POXEL - FR0012432516, éligible PEA-PME), société biopharmaceutique spécialisée dans le développement de traitements
89bio: Near And Long-Term Investment Cases Excite As Company Targets NASH Opportunity (NASDAQ:ETNB)
11:01pm, Wednesday, 14'th Oct 2020
89bio has emerged as a competitive player in the race to have a treatment approved for nonalcoholic steatohepatitis (“NASH”) - a potential multi-billion dollar market.
Terns Pharmaceuticals to Present Positive Data on Single-Agent and Combination NASH Programs at The Liver Meeting® Digital Experience 2020
12:00am, Wednesday, 14'th Oct 2020
Terns Pharmaceuticals to Present Positive Data on Single-Agent and Combination NASH Programs at The Liver Meeting® Digital Experience 2020
